Galantamine ( DrugBank: Galantamine )

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	3
127	Frontotemporal lobar degeneration	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-011093-15-DE (EUCTR)	16/11/2009	23/09/2009	The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory. - Dopamine and Acetylcholine for Attention and Memory	The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory. - Dopamine and Acetylcholine for Attention and Memory	Healthy volunteers MedDRA version: 12.0;Level: LLT;Classification code 10012271;Term: Dementia Alzheimer's type MedDRA version: 12.0;Classification code 10013113;Term: Disease Parkinson's	Trade Name: Nacom INN or Proposed INN: LEVODOPA Other descriptive name: L-Dopa Trade Name: Reminyl INN or Proposed INN: GALANTAMINE Other descriptive name: Galantamine hydrobromide	Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology	NULL	Not Recruiting			Female: yes Male: yes	80	Phase 2	Germany
2	EUCTR2008-006278-13-NL (EUCTR)	04/02/2009	15/10/2008	Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations.	Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations.	patients with advanced (>5 years) Parkinson's disease and visual hallucinations. MedDRA version: 9.1;Level: LLT;Classification code 10047570;Term: Visual hallucinations MedDRA version: 9.1;Classification code 10013113;Term: Disease Parkinson's	Trade Name: Reminyl Retard Trade Name: Sinemet 125 mg	UMCG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	10		Netherlands
3	NCT00211588 (ClinicalTrials.gov)	June 2004	13/9/2005	Galantamine Executive Function in Parkinson's Disease	Investigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's Disease	Parkinson's Disease	Drug: galantamine	Memorial Hospital of Rhode Island	Ortho-McNeil Neurologics, Inc.	Active, not recruiting	60 Years	85 Years	Both	90	N/A	United States

127. Frontotemporal lobar degeneration

Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00416169 (ClinicalTrials.gov)	May 2003	22/12/2006	A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia	An Open Pilot Study to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Pick's Disease/Frontotemporal Dementia /Pick Complex	Frontotemporal Dementia;Pick Complex	Drug: galantamine hydrobromide	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	NULL	Completed	30 Years	80 Years	Both	41	Phase 2	NULL